BRAF mutations are uncommon in papillary thyroid cancer of young patients

Thyroid

Volumn 15, Issue 4, 2005, Pages 320-325

  Penko, Karen ^a   Livezey, Jeffrey ^a   Fenton, Cydney ^a   Patel, Aneeta ^a   Nicholson, Diarmuid ^b   Flora, Michael ^a   Oakley, Kevin ^a   Tuttle, R Michael ^c   Francis, Gary ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PROTEIN RET;

ADOLESCENT; ADULT; CHILDHOOD CANCER; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN TISSUE; INCIDENCE; MALE; ONCOGENE RAS; PAPILLARY THYROID CANCER; PRIORITY JOURNAL; SCHOOL CHILD; THYROID CANCER;

ADOLESCENT; ADULT; CARCINOMA, PAPILLARY; CHILD; FEMALE; GENE REARRANGEMENT; HUMANS; MALE; MUTATION; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 18744402183     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.320     Document Type: Conference Paper

References (33)

1. DeGroot LJ, Kaplan EL, McCormick M, Straus FH 1990 Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414-424.
2. McClellan DR, Francis GL 1996 Thyroid cancer in children, pregnant women, and patients with Graves' disease. Endocrinol Metab Clin North Am 25:27-48.
3. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair C, Francis GL 1998 Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol (Oxf) 49:619-628.
4. Fenton C, Anderson J, Lukes Y, Dinauer CA, Tuttle RM, Francis GL 1999 Ras mutations are uncommon in sporadic thyroid cancer in children and young adults. J Endocrinol Invest 22:781-789.
5. Fenton CL, Patel A, Tuttle RM, Francis GL 2000 Autoantibodies to p53 in sera of patients with autoimmune thyroid disease. Ann Clin Lab Sci 30:179-183.
6. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL 2000 The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid 10:349-357.
7. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM 2000 The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 85:1170-1175.
8. Gydee H, O'Neill JT, Patel A, Bauer AJ, Tuttle RM, Francis G 2004 Differentiated thyroid carcinomas from children and adolescents express insulin-like growth factor-1 (IGF-1) and the IGF-1 receptor (IGF-1-R). Cancers with the most intense IGF-1-R expression may be more aggressive. Pediatr Res 55:1-7.
9. Straight A, Patel A, Fenton C, Dinauer C, Tuttle RM, Francis G 2002 Thyroid carcinomas that express telomerase follow a more aggressive clinical course for children and adolescents. J Endocrinol Invest 25:302-308.
10. Bongarzone I, Fugazzola L, Vingeri P, Mariani L, Mondellini P, Pacini F, Basolo F, Pinchera A, Pilotti S, Pierotti MA 1996 Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 81:2006-2009.
11. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research 57:1690-1694.
12. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954.
13. Mercer KE, Pritchard CA 2003 Raf proteins and cancer: B-Raf is identified as a mutational target. Biochemica et Biophysica Acta 1653:25-40.
14. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF Mutation in Papillary Thyroid Carcinoma. J Natl Cancer Inst 95:625-627.
15. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer. Cancer Res 63:1454-1457.
16. V599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 89:2414-2420.
17. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Bofelho T, Seruca R, Sobrinho-Simoes M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580.
18. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S 2003 BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22:6455-6457.
19. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsura A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implications of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397.
20. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404.
21. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567.
22. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A 2004 Alternative mutations of BRAF, RET, and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23:7436-7440.
23. Knauf JA, Kuroda H, Basu S, Fagin JA 2003 RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22:4406-4412.
24. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1057; discussion 1057-1058.
25. Kjellman P, Learoyd DL, Messina M, Weber G, Hoog A, Wallin G, Larsson C, Robinson BG, Zedenius J 2001 Expression of the RET proto-oncogene in papillary thyroid carcinoma and its correlation with clinical outcome. Br J Surg 88:557-563.
26. Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM 1998 Molecular analysis of new subtypes of ELE/RET rearrangements, their reciprocal transcripts and breakpoints in papillary thyroid carcinomas of children after Chernobyl. Oncogene 16:671-675.
27. Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM 1998 Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res 58:198-203.
28. Klugbauer S, Rabes HM 1999 The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene 18:4388-4393.
29. Learoyd DL, Messina M, Zedenius J, Guinea AI, Delbridge LW, Robinson BG 1998 RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas [see comments]. J Clin Endocrinol Metab 83:3631-3635.
30. Mayr B, Potter E, Goretzki P, Ruschoff J, Dietmaier W, Hoang-Vu C, Dralle H, Brabart G 1999 Expression of wild-type ret, ret/PTC and ret/PTC variants in papillary thyroid carcinoma in Germany. Langenbecks Arch Surg 384:54-59.
31. Pacini F, Elisei R, Romei C, Pinchera A 2000 RET proto-oncogene mutations in thyroid carcinomas: clinical relevance. J Endocrinol Invest 23:328-338.
32. Pisarchik AV, Ermak G, Demidchik EP, Mikhalevich LS, Kartel NA, Figge J 1998 Low prevalence of the ret/PTC3r1 rearrangement in a series of papillary thyroid carcinomas presenting in Belarus ten years post-Chernobyl. Thyroid 8:1003-1008.
33. Powers PA, Dinauer CA, Tuttle RM, Francis G 2004 The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents. J Pediatr Endocrinol Metab 17:339-343.